Combination Therapy for Ovarian Cancer
Author Information
Author(s): GJ Veldhuis, PHB Willemse, JH Beijnen, H Boonstra, H Piersma, WTA van der Graaf, EGE de Vries
Primary Institution: University Hospital, Groningen
Hypothesis
Can a combination of paclitaxel, ifosfamide, and cisplatin with supportive factors improve outcomes in ovarian cancer patients?
Conclusion
The combination therapy showed low tolerability and unexpected mortality, but a tendency for faster platelet recovery with rhIL-3.
Supporting Evidence
- Six of the nine evaluable patients had a tumour response.
- The overall median progression-free survival was 7 months.
- The overall mean survival was 13 months.
- Grade IV neutropenia occurred in 12 out of 52 courses.
- Patients treated with rhIL-3 showed a tendency to a faster platelet recovery.
Takeaway
Doctors tested a new treatment for ovarian cancer using three drugs together, but it made some patients very sick and had serious side effects.
Methodology
Patients received a combination of paclitaxel, ifosfamide, and cisplatin every 3 weeks, with some receiving additional rhIL-3.
Potential Biases
Potential selection bias due to the small number of patients and specific eligibility criteria.
Limitations
The study had a small sample size and high toxicity rates.
Participant Demographics
Patients aged 18-75 with histology-proven epithelial ovarian carcinoma.
Statistical Information
P-Value
P <0.001 for grade IV neutropenia and P=0.007 for gamma-glutamyltransferase.
Confidence Interval
95% CI 10-15 months for overall survival.
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website